MedTrace Logo

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05898256 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-12

No results posted yet for this study

Summary

This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma
  • Immune Checkpoint Inhibitors

Interventions

DRUG

Cadonilimab

10mg/kg administered intravenously (IV)

DRUG

Gemcitabine

1 g/m2, administered as an IV infusion within 30 minutes

DRUG

Cisplatin

80 mg/m2, administered as an IV infusion over 4 hours

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-07-31
Completion
2026-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898256 on ClinicalTrials.gov